News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

ImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107

Al's Comment:

I was hoping there would be more of a difference, like the phase 1 trial showed  (that trial showed a 50% 5 year survival). However, there were no side effects, and it is a simple shot in the arm, and it did increase progression free survival by 2 or 3 months.  We do not have all of the details yet so there may be some subgroups that did benefit a lot. 


Posted on: 12/15/2013

Click HERE for the press release

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc